ESTRO 2023 - Abstract Book

S386

Sunday 14 May 2023

ESTRO 2023

below the limit. Furthermore, almost half of the patients (12/27) had a reduction in the toxicity level for one or two OARs, showing an actual clinical benefit for the patient.

Conclusion Robust treatment plan optimization with reduced range uncertainty is feasible in clinical practice and allows for reduction of the OAR dose and toxicity level, which provides a rationale for further clinical implementation. Based on these results, we have clinically introduced DECT-based proton treatment planning for our neuro-oncological patients, accompanied with a reduced range uncertainty of 2%. MO-0479 Pencil beam scanning proton therapy for mediastinal lymphomas in deep inspiration breath-hold F. Horberger 1 , K. Andersson 2 , M. Enmark 3 , I. Kristensen 3,4 , A. Flejmer 5,6 , A. Edvardsson 3,7 1 Department of Hematology Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; 2 Department of Medical Physics, The Skandion Clinic, Uppsala, Sweden; 3 Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; 4 Department of Clinical Sciences, Oncology, Lund University, Lund, Sweden;